Review of 8 years of experience with Infanrix hexa™ (DTPa–HBV–IPV/Hib hexavalent vaccine)

References

• Atkinson WL, Pickering LK, Schwartz B et al. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices and the American Academy of Family Physicians. Morbid. Mortal. Wkly Rep.51(RR–2), 1–34 (2002).
   Google Scholar
• Mullany L. Considerations for implementing a new combination vaccine into managed care. Am. J. Manag. Care9, 23–29 (2003).
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Booy R, Weil-Olivier C, Van Damme P, Cohen R, Peltola H. Child vaccination policies in Europe: a report from the Summits of Independent European vaccination Experts. Lancet Infect. Dis.3, 103–108 (2003).
   PubMed Web of Science ®Google Scholar
• Expanded Programme on Immunization. Global Advisory Group Part I. Wkly Epidemiol. Rec.67 (1992).
   Google Scholar
• Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. BMJ5, 1033–1036 (1997).
   Google Scholar
• GlaxoSmithKline Biologicals, Rixensart, Belgium. Infanrix hexa™ European Summary of Product Characteristics. 17 November 2005.
   Google Scholar
• Safary A, André FE. Clinical experience with a yeast-derived hepatitis B vaccine. J. Chemother.1, 1096–8 (1989).
   PubMedGoogle Scholar
• André FE. Development and clinical application of new polyvalent combined pediatric vaccines. Vaccine17, 1620–1627 (1999).
   PubMed Web of Science ®Google Scholar
• Edwards KM, Decker MD. Pertussis vaccines. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders, PA, USA, 467–517 (2008).
   Google Scholar
• Schmitt HJ, Knuf M, Ortiz E, Sänger R, Uwamwezi MC, Kaufhold A. Primary vaccination of infants with diphtheria–tetanus–acellular pertussis–hepatitis B virus–inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J. Pediatr.137, 304–312 (2000).
   PubMed Web of Science ®Google Scholar
• Avdicová M, Prikazský V, Hudecková H et al. Immunogenicity and reactogenicity of a novel hexavalent DTPa–HBV–IPV/Hib vaccine compared with separate concomitant injections of DTPa–IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur. J. Pediatr.161, 581–587 (2002).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Blatter MM, Reisinger KS et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria–tetanus–acellular pertussis–hepatitis B–inactivated poliovirus–Haemophilus influenzae type b combination vaccination. Pediatr. Infect. Dis. J.21, 854–859 (2002).
   PubMed Web of Science ®Google Scholar
• Arístegui J, Dal-Ré R, Díez-Delgado J et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa–HBV–IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa–IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine21, 3593–3600 (2003).
   PubMed Web of Science ®Google Scholar
• Gabutti G, Zepp F, Schuerman L et al. Evaluation of the immunogenicity and reactogenicity of a DTPa–HBV–IPV combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections as 3, 5 and 11 months of age. Scand. J. Infect. Dis.36, 585–392 (2004).
   PubMed Web of Science ®Google Scholar
• Nolan T, Altmann A, Skeljo M, Streeton C, Schuerman L. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa–HBV–IPV/Hib vaccine. Vaccine23, 14–20 (2004).
   PubMed Web of Science ®Google Scholar
• Tejedor JC, Omeñaca F, García-Sicilia J et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria–tetanus–acellular pertussis–hepatitis B–inactivated polio–Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr. Infect. Dis. J.23, 1109–1115 (2004).
   PubMed Web of Science ®Google Scholar
• Zepp F, Knuf M, Heininger U et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine22, 2226–2233 (2004).
   PubMed Web of Science ®Google Scholar
• Black S, Nakasato C, Davis R et al. Two large Phase III, multicenter trials comparing primary vaccination with DTPa–HBV–IPV/Hib versus commercially available vaccines administered at separate sites. Presented at: 4th World Congress of the World Society for Pediatric Infectious Diseases (WSPID). Warsaw, Poland, 1–4 September 2005.
   Google Scholar
• Omeñaca F, Garcia-Sicilia J, García-Corbeira P et al. Response of preterm newborns to immunization with a hexavalent diphtheria–tetanus–acellular pertussis–hepatitis B virus–inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics116, 1292–1298 (2005).
   PubMedGoogle Scholar
• Tichmann I, Preidel H, Grunert D et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine23, 3272–3279 (2005).
   PubMed Web of Science ®Google Scholar
• Tichmann-Schumann I, Soemantri P, Behre U et al. Immunogenicity and reactogenicity of four doses of diphtheria–tetanus–three-component acellular pertussis–hepatitis B–inactivated polio virus–Haemophilus influenzae type b vaccine co-administered with 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J.24, 70–77 (2005).
   PubMed Web of Science ®Google Scholar
• Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa–HBV–IPV/Hib combination vaccine in healthy infants. Vaccine24, 4727–4736 (2006).
   PubMedGoogle Scholar
• Tejedor JC, Moro M, Ruiz-Contreras J et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria–tetanus–acellular pertussis–hepatitis B–inactivated polio–Haemophilus influenzae type b vaccine coadministered with two doses of a meningococcal C–tetanus toxoid conjugate vaccine. Pediatr. Infect. Dis. J.25, 713–720 (2006).
   PubMed Web of Science ®Google Scholar
• Tichmann I, Grunert D, Habash S et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccines and evaluation of booster vaccination. Hum. Vaccin.2, 249–254 (2006).
   PubMed Web of Science ®Google Scholar
• Gatchalian S, Bravo L, Cadorna-Carlos J et al. A hexavalent DTPa–HBV–IPV/Hib vaccine administered to Filipino infants at 6, 10 and 14 weeks and at 12–15 months of age, with or without a birth dose of HBV. Presented at: 12th Asia Pacific Congress of Pediatrics (APCP). Columbo, Sri Lanka, 5–9 September 2007.
   Google Scholar
• Heininger U; DTP-HBV-IPV-059 Study Group; DTP-HBV-IPV-096 Study Group, Sänger R, Jacquet JM, Schuerman L. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine25, 1055–1063 (2007).
   PubMedGoogle Scholar
• Omeñaca F, Garcia-Sicilia J, García-Corbeira P, Boceta R, Torres V. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria–tetanus–acellular pertussis–hepatitis B–inactivated polio virus/Haemophilus influenzae type b vaccine. Pediatrics119, e179–e185 (2007).
   PubMed Web of Science ®Google Scholar
• Zepp F, Behre U, Kindler K et al. Immunogenicity and safety of a tetravalent measles–mumps–rubella–varicella vaccine co-administered with a booster dose of a combined diphtheria–tetanus–acellular pertussis–hepatitis B–inactivated poliovirus–Haemophilus influenzae type b conjugate vaccine in healthy children aged 12–23 months. Eur. J. Pediatr.166, 857–864 (2007).
   PubMed Web of Science ®Google Scholar
• Kilpi T, Silfverdal SA, Nilsson L et al. Immunogenicity and reactogenicity of two diphtheria–tetanus–acellular pertussis–hepatitis B–inactivated polio virus–Haemophilus influenzae type b vaccines administered at 3, 5 and 11–12 months of age. Hum. Vaccin.5, 18–25 (2009).
   PubMed Web of Science ®Google Scholar
• Zinke M, Kappes R, Kindler K et al. Immune memory against hepatitis B persists in 7–9 year olds previously vaccinated with 4 doses of hexavalent DTPa–HBV–IPV/Hib vaccine. Presented at : 26th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Graz, Austria, 13–17 May 2008 (Abstract 629).
   Google Scholar
• Zinke M, Disselhoff J, the DTPa–HBV–IPV-110 and -111 study groups, Gartner B, Jacquet JM. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa–HBV–IPV/Hib. Presented at: The 26th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Graz, Austria, 13–17 May 2008 (Abstract 628).
   Google Scholar
• WHO. Hepatitis B vaccines. WHO position paper. Wkly Epidemiol. Rec.79, 253–264 (2004).
   PubMedGoogle Scholar
• Mansoor OD, Salama P. Should hepatitis B vaccine be used for infants? Expert Rev. Vaccines6(1), 29–33 (2007).
   PubMed Web of Science ®Google Scholar
• Mast E, Mahony F, Kane M, Margolis H. Hepatitis B vaccine. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders, PA, USA, 205–241 (2008).
   Google Scholar
• Van Herck K, Van Damme P. Benefits of early hepatitis B immunization programs for newborns and infants. Pediatr. Infect. Dis. J.27, 861–869 (2008).
   PubMedGoogle Scholar
• Zanetti A, Mariano A, Romanò L et al. Long-term immunogenicity of hepatitis B vaccinations and policy for booster: an Italian multicentre study. Lancet366, 1379–1384 (2005).
   PubMed Web of Science ®Google Scholar
• Da Villa G, Romanò L, Sepe A et al. Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine25, 3133–3136 (2007).
   PubMed Web of Science ®Google Scholar
• McIntyre P. Invasive Haemophilus influenzae type b disease in Australia: the beginning of the end? Med. J. Aust.156. 516–518 (1992).
   PubMedGoogle Scholar
• Harris A, Hendrie D, Bower C, Payne J, de Klerk N, Stanley F. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP. Med. J. Aust.160, 483–488 (1994).
   PubMed Web of Science ®Google Scholar
• Garpenholt O, Silfverdal SA, Hugosson S et al. The impact of Haemophilus influenzae type b vaccination in Sweden. Scand. J. Infect. Dis.28, 165–169 (1996).
   PubMed Web of Science ®Google Scholar
• Chandran A, Watt JP, Santosham M. Haemophilus influenzae vaccines. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders, PA, USA 157–176 (2008).
   Google Scholar
• Schmitt HJ. Immunogenicity and reactogenicity of two Haemophilus influenzae type b tetanus conjugate vaccines administered by reconstituting with diphtheria–tetanus–acellular pertussis vaccine or given as separate injections. Presented at: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA 17–20 September 1995.
   Google Scholar
• Eskola J, Olander RM, Hovi T, Litmanen L, Peltola S, Käyhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet348, 1688–1692 (1996).
   PubMed Web of Science ®Google Scholar
• Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria–tetanus–pertussis containing acellular pertussis. Lancet354, 2063–2068 (1999).
   PubMed Web of Science ®Google Scholar
• Dagan R, Poolman JT, Zepp F. Combination vaccine containing DTPa–Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev. Vaccines7(1), 97–115 (2008).
   PubMed Web of Science ®Google Scholar
• Decker MD. Edwards KM, Bogaerts HH. Combination vaccines. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders, PA, USA, 1069–1101 (2008).
   Google Scholar
• Zepp F, Schmitt HJ, Kaufhold A et al. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib–DTPa–HBV combined vaccine. Eur. J. Pediatr.156, 18–24 (1997).
   PubMed Web of Science ®Google Scholar
• Kalies H, Verstraeten T, Grote V et al. Four and one-half-year follow-up of the effectiveness of diphtheria–tetanus toxoids–acellular pertussis/Haemophilus influenzae type b and diphtheria–tetanus toxoids–acellular pertussis–inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr. Infect. Dis. J.23, 944–950 (2004).
   PubMed Web of Science ®Google Scholar
• Kalies H, Groendahl B, Schmitt HJ, Siedler A, von Kries R. Effectiveness of hexavalent vaccines against invasive haemophilus influenzae type b disease in Germany. Presented at: 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Valencia, Spain, 18–20 May 2005.
   Google Scholar
• Kalies H, Grote V, Siedler A, Gröndahl B, Schmitt HJ, von Kries R. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure. Vaccine26, 2545–2552 (2008).
   PubMed Web of Science ®Google Scholar
• Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J. Infect. Dis.188, 481–485 (2003).
   PubMed Web of Science ®Google Scholar
• Fitzgerald M, Canny M, O’Flanagan D. Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill.10(9), E050929.2 (2005).
   PubMedGoogle Scholar
• Steinhoff M, Goldblatt D. Conjugate Hib vaccines. Lancet361, 360–1 (2003).
   PubMed Web of Science ®Google Scholar
• Denoël PA, Goldblatt D, de Vleeschauwer I, Jacquet JM, Pichichero ME, Poolman JT. Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria–tetanus–acellular pertussis/Hib combination vaccines. Clin. Vaccine Immunol.14, 1362–1369 (2007).
   PubMedGoogle Scholar
• Cohen R, Schuerman L. Reactogenicity of a new DTPa–HBV–IPV (+ & /Hib) vaccines after primary and booster doses. Presented at: 18th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Noordwijk, The Netherlands, 3–5 May 2000.
   Google Scholar
• Saenger R, Maechler G, Potreck M et al. Booster vaccination with hexavalent DTPa–HBV–IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa–IPV/Hib + HBV administered separately. Vaccine23, 1135–1143 (2005).
   PubMedGoogle Scholar
• Rennels MB, Deloria MA, Pichichero ME et al. Extensive swelling after booster doses of acellular pertussis–tetanus–diphtheria vaccines. Pediatrics105, e12 (2000).
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Beutel K, Schuind A et al. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J. Pediatr.130, 616–623 (1997).
   PubMed Web of Science ®Google Scholar
• Saari TN; American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics112, 193–198 (2003).
   PubMed Web of Science ®Google Scholar
• Kroger AT, Atkinson WL, Marcuse EK, Pickering LK; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly Recomm. Rep.55(RR-15), 1–48 (2006).
   PubMedGoogle Scholar
• Baraff LJ, Ablon WJ, Weiss RC. Possible temporal association between diphtheria–tetanus toxoid–pertussis vaccination and sudden infant death syndrome. Pediatr. Infect. Dis.2, 7–11 (1983).
   PubMedGoogle Scholar
• Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev.18, 326–382 (2005).
   PubMed Web of Science ®Google Scholar
• Hoffman HJ, Hunter JC, Damus K et al. Diphtheria–tetanus–pertussis immunization and sudden infant death: results of the National Institute of Child Health and Human Development Cooperative Epidemiological Study of Sudden Infant Death Syndrome risk factors. Pediatrics79, 598–611 (1987).
   PubMed Web of Science ®Google Scholar
• Griffin MR, Ray WA, Livengood JR, Schaffner W. Risk of sudden infant death syndrome after immunization with the diphtheria–tetanus–pertussis vaccine. N. Engl. J. Med.319, 618–623 (1988).
   PubMed Web of Science ®Google Scholar
• Keller-Stanislawski B, Löwer J. Todesfälle in zeitlichem Zusammenhang mit Sechsfachimpfung. Kinder und Jugendarzt34, 608–613 (2003).
   Google Scholar
• von Kries R, Toschke AM, Straßburger K et al. Sudden and unexpected deaths after the administration of hexavalent vaccines (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilius influenzae type b): is there a signal? Eur. J. Pediatr.164, 61–69 (2005).
   PubMed Web of Science ®Google Scholar
• von Kries R. Comment on B. Zinka et al. Unexplained cases of sudden infant death shortly after hexavalent vaccination. Vaccine24, 5783–5784 (2006).
   PubMed Web of Science ®Google Scholar
• Vennemann MM, Höffgen M, Bajanowski T, Hense HW, Mitchell EA. Do immunisations reduce the risk for SIDS? A meta-analysis. Vaccine25, 4875–4879 (2007).
   PubMedGoogle Scholar
• Meyerhoff AS, Greenberg DP, Jacobs RJ. Predicted effects of a new combination vaccine on childhood immunization coverage rates and vaccination activities. Dis. Manage. Health Outcomes13, 317–326 (2005).
   Google Scholar
• Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr. Infect. Dis. J.25, 507–512 (2006).
   PubMed Web of Science ®Google Scholar
• Marshall GS, Happe LE, Lunacsek OE et al. Use of combination vaccines is associated with improved coverage rates. Pediatr. Infect. Dis. J.26, 496–500 (2007).
   PubMed Web of Science ®Google Scholar
• Tozzi AE, Azzari C, Bartolozzi G, Esposito S, Fara GM, Giudice ML. Can hexavalent vaccines be simultaneously administered with pneumococcal and meningococcal conjugate vaccines? Hum. Vaccin.3, 252–259 (2007).
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Habermehl P, Knuf M, Ypma E, Borkowski A. Safety, reactogenicity and immunogenicity/priming following 2 vs. 3 doses of a meningococcal C conjugate vaccine (MCC) given concomitantly with DTaP-IPV-HBV/Hib vaccine to infants. Presented at: 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Valencia, Spain, 18–20 May 2005.
   Google Scholar
• Schmitt HJ, Maechler G, Habermehl P et al. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae–Neisseria meningitidis serogroup C conjugate vaccine. Clin. Vaccine Immunol.14, 426–434 (2007).
   PubMedGoogle Scholar
• Vesikari T, Prymula R, Schuster V et al. Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphtheria–tetanus–pertusis(DTPa)-combined vaccines in healthy infants from Europe. Presented at: 24th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Basel, Switzerland, 3–5 May 2006.
   Google Scholar
• Zepp F. ‘My Generation’ – an international study investigating mothers’ concerns about vaccination: analysis of initial findings. Presented at: 4th Congress of the World Society for Pediatric Infectious Diseases (WSPID). Warsaw, Poland 1–4 September 2005 (Abstract G-915).
   Google Scholar
• Offit PA, Quarles J, Gerber MA et al. Addressing parents’ concerns: do multiple vaccines overwhelm or weaken the infant’s immune system? Pediatrics109, 124–129 (2002).
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Booy R, Aston R et al. How to optimise the coverage rate of infant and adult immunisations in Europe. BMC Med.5, 11 (2007).
   PubMed Web of Science ®Google Scholar
• WHO. 2005. Global Advisory Committee on Vaccine Safety, 9–10 June 2005. Wkly Epidemiol. Rec.80, 242–247 (2005).
   PubMedGoogle Scholar
• Scott DA, Komjathy SF, Hu BT et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine25, 6164–6166 (2007).
   PubMed Web of Science ®Google Scholar